Cynthia A Gates

This inventor holds 11 USPTO granted patents, plus 1 CIPO patent. Top assignees: Merrell Pharmaceuticals, Inc., Aventis Pharmaceuticals Inc., Merrell Dow Pharmaceuticals. Active years: 1992-2002.

USPTO Granted Patents = 11

% Patents Active = 90.9

CIPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Fairfield, OH (US) (1992 - 2002)
Cambridge, MA (US) (2002)

Company Filing History:

7 out of 194

Merrell Pharmaceuticals, Inc.

patents

2 out of 207

Aventis Pharmaceuticals Inc.

patents

2 out of 455

Merrell Dow Pharmaceuticals

patents

Years Active: 1992-2002

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6413951 - 20-fluoro-17(20)-vinyl steroids (2002-07-02),

2. 6365597 - 4-aza steroids (2002-04-02),

3. 5990328 - Process for the preparation of 4-amino-.DELTA.4-3-ketosteroids via (1999-11-23),

4. 5977094 - Methods and compositions using .DELTA..sup.16 unsaturated C.sub.17 (1999-11-02),

5. 5965550 - Process for the preparation of 4-amino-.DELTA..sup.4 -3-ketosteroids via (1999-10-12),

6. 5965548 - .increment..sup.16 unsaturated C.sub.17 heterocyclic steroids useful as (1999-10-12),

7. 5869475 - Certain 3-ketosteroids used to inhibit steroid 5.alpha.-reductase (1999-02-09),

8. 5750744 - Process for the preparation of 4-amino- 4-3-ketosteroids via 4-nitro- (1998-05-12),

9. 5677293 - 16 unsaturated C17 heterocyclic steroids useful as steroid C17-20 lyase (1997-10-14),

10. 5486511 - 4-amino-17.beta.-(cyclopropyloxy)androst-4-en-3-one, (1996-01-23),

11. 5143909 - Aminosteroids in a method for inhibiting C17-20 lyase (1992-09-01),

Title: Cynthia A Gates: Innovator in Steroid Chemistry

Introduction

Cynthia A Gates is a prominent inventor based in Fairfield, OH (US). She has made significant contributions to the field of steroid chemistry, holding a total of 11 patents. Her work focuses on the development of compounds that have therapeutic applications in treating various androgen and estrogen-mediated disorders.

Latest Patents

Cynthia's latest patents include innovative compounds such as 20-fluoro-17(20)-vinyl steroids. This invention relates to several compounds, including 20&xgr;-fluoropregna-4,17(20)-dien-3-on-21-oic acid ethyl ester and 20&xgr;-fluoropregna-5,17(20)-dien-3&bgr;,21-diol. These compounds are designed to inhibit C lyase, 5&agr;-reductase, and C-hydroxylase, and are intended for the treatment of disorders such as benign prostatic hyperplasia, prostate cancer, and breast cancer. Additionally, her work addresses conditions related to the over-synthesis of cortisol, including Cushing's Syndrome.

Another significant area of her research involves 4-aza steroids, which includes compounds like 4-aza-17&bgr;-(cyclopropoxy)-androst-5&agr;-androstan-3-one. These compounds also target androgen and estrogen-mediated disorders and are designed for combination therapy with known androgen-receptor antagonists, such as flutamide.

Career Highlights

Cynthia has worked with notable companies in the pharmaceutical industry, including Merrell Pharmaceuticals, Inc. and Merrell Dow Pharmaceuticals. Her experience in these organizations has contributed to her expertise in developing innovative therapeutic compounds.

Collaborations

Throughout her career, Cynthia has collaborated with esteemed colleagues such as Philip M Weintraub and Michael R Angelastro. These partnerships have further enhanced her research and development efforts in steroid chemistry.

Conclusion

Cynthia A Gates is a distinguished inventor whose work in steroid chemistry has led to significant advancements in the treatment of various medical conditions. Her innovative patents and collaborations reflect her commitment to improving healthcare through scientific research.